The latter may prove to be a useful asset in the arsenal of anti-GRPR radioactive drugs, by internalizing in cancer cells while evading binding to and activation of bombesin receptor subtypes other than the GRPR in the gut. The gene discussed is GRPR; the disease is cancer.